Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

High-dose adjuvant interferon therapy for melanoma

A G Licata1

  • 1Department of Medicine, University of Vermont College of Medicine, Burlington, USA.

Dermatology Nursing
|January 5, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Malignant melanoma and other second cutaneous malignancies in cutaneous T-cell lymphoma. The influence of additional therapy after total skin electron beam radiation.

Archives of dermatologyยท1995
See all related articles

High-dose interferon is now approved as adjuvant therapy for high-risk melanoma patients, especially those with lymph node involvement. This review covers treatment indications and potential side effects.

Area of Science:

  • Oncology
  • Dermatology
  • Immunotherapy

Background:

  • Melanoma remains a significant health concern, particularly in high-risk patient groups.
  • Adjuvant therapy aims to reduce recurrence risk after primary treatment.
  • Regional lymph node metastasis is a critical prognostic factor in melanoma.

Purpose of the Study:

  • To review the indications for high-dose interferon as adjuvant therapy in high-risk melanoma.
  • To summarize the supporting data for this treatment approval.
  • To discuss the known side effects associated with high-dose interferon therapy.

Main Methods:

  • Literature review of clinical trials and relevant studies.
  • Analysis of data supporting the efficacy of interferon in adjuvant melanoma treatment.

Related Experiment Videos

  • Compilation of reported side effect profiles from clinical studies.

    • Main Results:

    • High-dose interferon has gained regulatory approval for specific high-risk melanoma patient populations.
    • Evidence supports its use in reducing the risk of recurrence in patients with regional lymph node disease.
    • The treatment is associated with a spectrum of potential side effects that require careful management.

    Conclusions:

    • High-dose interferon represents a new adjuvant treatment option for select high-risk melanoma patients.
    • Understanding treatment indications and side effect management is crucial for optimal patient care.
    • Further research may refine the role of interferon in melanoma adjuvant therapy.